OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Publication Speed (median values for papers published in 2022): Submission to First Decision: 5 weeks; Submission to Acceptance: 14 weeks; Acceptance to Publication: 11 days (1-2 days of FREE language polishing included)
Biomarkers of Aging
Submission Deadline: November 30, 2021 (Open) Submit Now
Annamaria Zaia, PhD
Gerontologic and Geriatric Research Department, Center of Innovative Models and Technology for Ageing Care, Scientific Direction, IRCCS INRCA, 60121 Ancona, Italy
Research Interests: Biomarkers of aging; Parkinson’s disease; Alzheimer's disease; aging; aging care; osteoporosis; image processing; models; biomedical imaging; medical and biomedical image processing; biomedical signal processing
About This Topic
Biomarkers of aging are indices for identifying age-related change(s) in body function, structure, or composition usable as a measure of “biological” age and to predict the onset of age-related diseases and/or residual lifetime more accurately than chronological age.
Despite many candidate biomarkers of human ageing have been proposed, no single measurement has been proven to serve for its own scope. This is because of the high degree of inter- and intra-individual variability of human beings due to different rate of aging.
One classical definition of aging is a “progressive, generalized impairment of functions responsible for increased vulnerability to environmental challenges and growing risk of disease and death”. Considerable efforts have been devoted to unveiling the underlying mechanisms; nevertheless, a comprehensive and universal theory of aging is still lacking.
Integrative and evolutionary theories better describe aging as a multi-factorial process involving complex genetic-environmental interactions responsible for the heterogeneity observed in the senescent phenotype.
In the light of this holistic point of view of aging phenomena, new research approaches are needed to characterize the senescent phenotype evolving with time as normal aging, pathological aging or successful aging. It would give insight into the search of good biomarkers of aging able to discriminate between physiological and pathological aging as well as between age-dependent and age-associated diseases, two main tasks dealing with aging well.
This special issue entitled “Biomarkers of Aging” welcomes research articles on innovative approaches and reviews on the current state of the art. Articles giving diagnostic and therapeutic perspectives for aging well are encouraged.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.